ORIGINAL ARTICLE - BREAST ONCOLOGY

Annals of SURGICALONCOLOGY OFFICIAL JOURNAL OF THE SOCIETY OF SURGICAL ONCOLOGY



Impact that Timing of Genetic Mutation Diagnosis has on Surgical Decision Making and Outcome for BRCA1/BRCA2 Mutation Carriers with Breast Cancer

Akiko Chiba, MD¹, Tanya L. Hoskin, MS², Emily J. Hallberg, MPH², Jodie A. Cogswell², Courtney N. Heins, BS², Fergus J. Couch, PhD³, and Judy C. Boughey, MD¹

¹Department of Surgery, Mayo Clinic, Rochester, MN; ²Department of Health Sciences Research, Mayo Clinic, Rochester, MN; ³Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN

ABSTRACT

Background. Deleterious BRCA mutation carriers with breast cancer are at increased risk for additional breast cancer events. This study evaluated the impact that timing of identification of BRCA+ status has on surgical decision and outcome.

Methods. The authors reviewed all BRCA carriers at their institution whose breast cancer was diagnosed between January 1996 and June 2015. Patient surveys, medical records, and institutional databases were used to collect data. Differences in surgical choice were analyzed using the chi-square test, and rates of subsequent breast cancer events were estimated using the Kaplan–Meier method.

Results. The study investigated 173 BRCA carriers with breast cancer (100 BRCA1, 73 BRCA2). Of the women with known BRCA mutation before surgery and unilateral stages 0 to 3 breast cancer (n = 63), 12.7 % underwent lumpectomy, 4.8 % underwent unilateral mastectomy (UM), and 82.5 % underwent bilateral mastectomy (BM). These surgical choices differed significantly (p < 0.0001) from those of patients unaware of their mutation at the time of surgery (n = 93) (51.6 % had lumpectomy, 19.4 % had UM, 29 % had BM). Of the patients with BRCA mutation identified after surgery who underwent lumpectomy or UM, 36 (59 %) of 66 underwent delayed BM. The patients with BRCA+ known before diagnosis presented with significantly lower-stage disease (p = 0.02) at diagnosis

J. C. Boughey, MD e-mail: boughey.judy@mayo.edu (69 % stage 0 or 1) than those whose BRCA mutation was identified after cancer diagnosis (40 % stage 0 or 1). **Conclusions.** The study findings showed that BRCA mutation status influences surgical decision. The rates of BM were higher for the patients with BRCA mutation known before surgery. Identification of BRCA mutation after surgery frequently leads to subsequent breast surgery. Genetic testing before surgery is important for patients at elevated risk for BRCA mutation.

In 1994 and 1995, BRCA1 and BRCA2 tumor-suppressor genes were respectively sequenced.^{1,2} Approximately 3 to 5 % of breast cancer cases are associated with germline mutations in BRCA1/BRCA2.^{3,4} Carriers of the BRCA1/BRCA2 mutations have an increased lifetime risk for the development of breast cancer,^{5,6} and mutation carriers with breast cancer are at increased risk for future breast cancer events.

Knowledge of a deleterious BRCA mutation can influence surgical treatment decisions for patients with a diagnosis of breast cancer.⁷ These women may opt for more aggressive surgical treatment such as bilateral mastectomy.^{8,9} For BRCA mutation carriers with a diagnosis of breast cancer who undergo breast-conserving surgery, some studies suggest that the risk of ipsilateral breast cancer is higher than for patients with sporadic breast cancer.¹⁰ Also, the risk of contralateral breast cancer development is significantly higher for BRCA mutation carriers than for noncarriers.^{10–12}

The current study evaluated how the surgical decisions of BRCA mutation carriers with a diagnosis of breast cancer varied based on timing of identification of BRCA mutation status relative to surgery for their index breast

[©] Society of Surgical Oncology 2016

First Received: 7 April 2016; Published Online: 23 June 2016

cancer. Additionally, we sought to evaluate breast cancer outcomes by surgical procedure.

METHODS AND MATERIALS

Study Design

With Institutional Review Board approval, we reviewed all BRCA1/BRCA2 deleterious mutation carriers at our institution whose breast cancer was diagnosed between 1 January 1996 and 30 June 2015 using a systematic search of the electronic medical record. Individuals known to be BRCA mutation carriers through other research efforts were used to validate the search findings. A study coordinator reviewed the search results to verify testing results and abstract relevant genetic testing information.

From this cohort of BRCA carriers, female patients with a deleterious gene mutation who had a diagnosis of breast cancer were identified for this study. A chart review then extracted additional information from the medical record including age at breast cancer diagnosis, operation performed for the index breast cancer, subsequent breast surgery, timing of the BRCA test result, clinical and pathologic staging, histology, hormone receptor status, and information regarding systemic therapy and radiation therapy and patient outcome.

The patients were categorized into three groups: group 1 (patients whose BRCA+ status was known before their cancer diagnosis), group 2 (patients whose BRCA+ status was identified during their cancer workup, in the time between their breast cancer diagnosis and their index breast cancer surgery), group 3 (patients whose BRCA+ status was identified at any time after their index breast cancer surgery).

Statistical Analysis

Differences among the groups were assessed using the chi-square test for type of surgery, the Wilcoxon rank-sum test for age at diagnosis, and the Cochran-Armitage trend test for clinical stage. The Kaplan-Meier method with 95 % confidence intervals (CIs) calculated based on the logarithm of the survival function was used to estimate long-term outcomes including contralateral breast cancer, local-regional recurrence, and freedom from breast cancer, in which patients were counted as events if they expericontralateral breast enced cancer, local-regional recurrence, or distant recurrence. Because many patients underwent second operations (e.g., delayed bilateral mastectomy) during the follow-up period, this time-varying covariate of surgery type was handled in two ways:

- 1. For simple Kaplan–Meier estimates, patients were censored at the time of the second surgery when estimation per procedure rates was performed.
- 2. For tests across surgery type, Cox proportional hazards regression with surgery type as a time-varying covariate was used to partition the follow-up time according different surgery types over time.

Analysis was performed using SAS (version 9.3) and the survival package in R (version 3.0.2).¹³ All p values lower than 0.05 were considered statistically significant.

RESULTS

A cohort of 191 female BRCA mutation carriers with a diagnosis of breast cancer was identified. Among these women, 11 (5.8 %) who had undergone their index surgery outside our institution without sufficient survey or medical record data to confirm the index surgical treatment were excluded from the study as well as another 4 patients (2.1 %) who had unknown timing of their BRCA mutation testing result. Two patients who had breast cancer identified as an occult malignancy at the time of bilateral prophylactic mastectomy and one patient who presented with breast cancer after bilateral prophylactic skin-sparing mastectomy were also excluded. Thus, the study cohort consisted of 173 women with sufficient data to classify the timing of BRCA mutation testing result relative to surgical decision making and to characterize the initial surgical management. Of these women, 100 (58 %) were BRCA1 deleterious mutation carriers, and 73 (42 %) were BRCA2 deleterious mutation carriers.

Table 1 shows the patient demographics, tumor characteristics, systemic and radiation treatment, and type of breast surgery for the 173 patients, of whom 160 (92 %) presented with unilateral breast cancer and 13 (8 %) presented with bilateral disease. Of the 173 patients, 15 (9 %) were known BRCA carriers who developed breast cancer (group 1), 56 (32 %) were found to be BRCA carriers at the time of cancer diagnosis but before surgery (group 2), and 102 (59 %) were found to be BRCA carriers after initial surgical treatment (group 3). Three of the 173 patients did not undergo primary surgery due to stage 4 disease at presentation, and one patient underwent axillary dissection alone due to axillary metastasis without breast primary surgery. The timing of BRCA mutation testing relative to cancer diagnosis did not differ significantly between the BRCA1 and BRCA2 carriers. Of the BRCA1 carriers, 12 % (12/100) had their mutation status identified before breast cancer diagnosis, whereas 4 % (3/73) of the BRCA2 mutation carriers were aware of their mutation before their breast cancer diagnosis (p = 0.073).



FIG. 1 Bar chart showing clinical stage distribution for female subjects whose BRCA mutation status was identified before breast cancer diagnosis versus after diagnosis

The median age at breast cancer diagnosis was 45 years (range 21–79 years), and the median age at identification of BRCA mutation status was 46 years (range 21–79 years). The median age at breast cancer diagnosis did not differ significantly by timing group and was 46 years (range 28–79 years) for group 1, 41 years (range 21–71 years) for group 2, and 45 years (range 25–72 years) for group 3 (p = 0.34).

The women with BRCA mutation status known before diagnosis (group 1) demonstrated a significantly lower clinical stage at diagnosis (p = 0.02) than the women whose BRCA mutation was identified after their breast cancer diagnosis (groups 2 and 3) (Fig. 1). Of the patients with known BRCA mutation status prior to breast cancer development, 69 % presented with stage 0 or 1 disease, and none of these patients presented with either stage 3 or 4 disease. Of the known BRCA+ patients (Group 1) 73 % (11/15) were compliant with screening guidelines. Of the patients unaware of their BRCA mutation, 40 % presented with stage 0 or 1 disease, and 20 % presented with stage 3 or 4 disease.

Clinical stage did not vary significantly between BRCA1 and BRCA2 carriers (p = 0.52), who had stage 0/1 in 44 % and 41 %, respectively. Estrogen receptor-negative (ER–) and human epidermal growth factor receptor 2-negative (HER2–) invasive cancer was significantly more likely in BRCA1 carriers (50 %) than in BRCA2 carriers (32 %) (p = 0.04). The findings showed no significant association between the BRCA gene and HER2 + disease (9 % BRCA1, 6 % BRCA2; p = 0.53). Receptor status did not vary significantly across groups 1, 2, and 3 (p = 0.25). The clinical stage was significantly higher for



FIG. 2 Bar chart showing distribution of initial surgery choice for 156 women with unilateral stages 0–3 breast cancer whose mutation status was identified before surgery versus after surgery

ER-/HER2- cancer (p = 0.03), with 50 % of cases classified as stage 2 and 27 % as stage 3 compared with 38 % classified as stage 2 and 16 % as stage 3 or 4 among other biologic subtypes, but was not significantly associated with the choice of surgery (p = 0.53).

Patients Presenting with Unilateral Cancer

Among 156 women with unilateral breast cancer undergoing breast surgery for stages 0 to 3 disease, those with BRCA mutation known before surgery chose the following surgeries: lumpectomy (13 %), UM (5 %), and BM (83 %). These rates differed significantly (p < 0.0001) from the patients whose BRCA mutation was not identified until after surgery (lumpectomy, 52 %; UM, 19 %; and BM, 29 %) (Fig. 2). Among the patients with BRCA mutation identified after surgery who underwent lumpectomy or UM at their index surgery (n = 66), 26 (39 %) of 66 patients subsequently underwent BM for risk reduction after identification of mutation status, and another 2 (3 %) of the 66 patients underwent risk-reducing BM after initial surgery but before mutation testing. Additionally, 11 (17 %) of the 66 patients underwent subsequent BM as part of subsequent treatment of disease (6 for contralateral breast cancer, 4 for local-regional recurrence, and 1 for margin control). Thus, altogether, 39 (59 %) of the 66 patients underwent delayed bilateral mastectomy.

During a median follow-up period of 3.4 years (range 0– 17 years), 33 of the patients with stages 0 to 3 unilateral breast cancer experienced one or more subsequent breast cancer events. The distribution of the first event type was 11 local-regional recurrences, 11 distant recurrences, and TABLE 1 Characteristics of 173 female subjects

Median age at breast cancer diagnosis: years (range) 45 (21-79) Median age at genetic mutation testing: years (range) 46 (21-79) Timing of genetic setting: learns (range) 15 (8.7) Genetic testing learns to breast cancer diagnosis and surgery 15 (8.7) Genetic testing after surgery 160 (22.5) Cenetic testing after surgery 160 (25.5) Unilateral breast cancer 160 (25.5) O 10 (7.3) 1 49 (35.8) 2 2 (16.1) 3 2 (16.1) 4 3 (22.2) Unknown 36 Nodal status 8 Restroper resport status 7 (45.5) Positive 98 (59.4) Vestore 7 (45.5) Unknown 36 Stotopan receptor status 7 (45.5) Positive 90 (7.4) Vestore 7 (45.9) Unknown 14 HER2 status 7 (45.5) Positive 90 (7.4) None 12 (12.1) None 12 (12.1)<		n = 173 n (%)
Median ge ag enecie mutication itsning years (mape)46 (21-79)Timing of genetic testing relative to breast cancer diagnosis and surgery56 (32.4)Genetic testing after diagnosis but before surgery56 (32.4)Genetic testing after diagnosis but before surgery102 (59.0)Laterality11 (7.5)Billateral breast cancer106 (92.5)O inicial TNM stage106 (92.5)O inicial TNM stage21 (61.1)040 (55.8)223 (21.1)440 (55.8)324 (21.1)440 (55.8)323 (21.1)440 (55.8)324 (21.1)440 (55.8)324 (21.1)440 (55.8)324 (21.1)440 (55.8)324 (21.1)440 (55.8)324 (21.1)440 (55.8)423 (22.1)440 (55.8)434 (21.1)440 (21.1)440 (21.1)440 (21.1)440 (21.1)440 (21.1)440 (21.1)440 (21.1)440 (21.1)440 (21.1)440 (21.1)440 (21.1)440 (21.1)440 (21.1)440 (21.1)440 (21.1)440 (21.1)440 (21.1)440 (21.1)440 (21.1)	Median age at breast cancer diagnosis: years (range)	45 (21–79)
Timite of genetic texting tealing to be est cancer diagnosis and surgery16 (R)Genetic testing after surgers56 (22.4)Genetic testing after diagnosis hab befors surgery10 (25.90)Laterating13 (7.5)Unitateral breast cancer10 (02.5)Clinical TMM stage10 (7.3)149 (55.8)23 (23.7)32 (16.1)43 (22.9)140 (55.8)23 (28.7)32 (16.1)43 (22.9)140 (55.8)23 (28.7)33 (28.7)33 (28.7)33 (28.7)33 (28.7)33 (28.7)33 (28.7)33 (28.7)43 (28.7)43 (28.7)53 (28.7)	Median age at genetic mutation testing: years (range)	46 (21–79)
Genetic testing herer beast cancer diagnosis15 (8.7)Genetic testing after diagnosis but before surgery56 (32.4)Genetic testing after surgery102 (250)Laterality16 (02.5)Biltneral breast cancer16 (02.5)Clinikard Threast cancer10 (03.5)110 (03.5)110 (03.5)110 (03.5)110 (03.5)110 (03.5)110 (03.5)210 (03.5)120 (01.6)010 (03.5)120 (01.6)149 (35.8)220 (01.6)220 (01.6)220 (01.6)220 (01.6)220 (01.6)220 (01.6)220 (01.6)220 (01.6)220 (01.6)220 (01.6)220 (01.6)220 (01.6)220 (01.6)220 (01.6)220 (01.6)220 (01.6)220 (01.6)220 (01.6)220 (01.6)220 (01.7)220 (01.7)220 (01.7)220 (01.7)220 (01.7)220 (01.7)220 (01.7)220 (01.7)220 (01.7)220 (01.7)220 (01.7)220 (01.7)220 (01.7)220 (01.7)2<	Timing of genetic testing relative to breast cancer diagnosis and surgery	
Genetic testing after surgey56 (32.4)Genetic testing after surgey102 (50.0)Learality13 (7.5)Unilateral breast cancer13 (7.5)Unilateral breast cancer10 (7.3)1010 (7.3)1010 (7.3)149 (35.8)23 (38.7)3221 (6.1)3221 (6.1)42 (2.1)42 (2.1)142 (2.1)153210 (7.3)42 (3.1)210 (7.3)3333 (3.87)33 (3.87)33 (3.87)43 (2.2)Unknown3 (2.2)Notal stats8 (5.9)Extragen receptor status8 (5.9)Extragen receptor status10 (7.8)Positive8 (5.4)Negative10 (7.8)Valuateration10 (7.8)Negative10 (7.8)Negative10 (7.8)Unknown or nat aplicabe8 (30.9)Nord10 (2.2)Nord10 (2.2)Nord10 (2.2)Nord2 (2.1)Nord2 (2.1)Nord2 (2.1)Nord2 (2.2)Nord2 (2.2)Unknown or nat aplicabe4 (2.3)Nord2 (2.1)Nord2 (2.1)Nord2 (2.1)Nord2 (2.1)Nord2 (2.1)Nord2 (2.1) <tr< td=""><td>Genetic testing before breast cancer diagnosis</td><td>15 (8.7)</td></tr<>	Genetic testing before breast cancer diagnosis	15 (8.7)
Genetic testing after surgery102 (59.0)Laterality160 (92.5)Unilateral breast cancer160 (92.5)Clinical TNM stage49 (53.8)249 (53.8)253 (38.7)322 (11.1)43 (22.1)332 (11.1)43 (22.1)Unknown36 (59.4)Nedal Jattas98 (69.4)Positive98 (69.4)Positive86 (54.1)Vestopen receptor status86 (54.1)Vestopen receptor status86 (54.1)Vuknown86 (54.1)Vestopen receptor status18 (92.2)Unknown or ont applicable16 (92.2)Unknown or ont applicable60 (34.7)Unknown or ont applicable86 (50.9)Noed'21 (12.1)Unknown or ont applicable86 (50.9)Noed'42 (23.1)Vestopic therapy45 (27.1)Vestopic therapy45 (27.1)Noed(svant stepery12 (12.9)Noed(svant stepery12 (12.9)Noed(svant stepery12 (12.9)Noed(svant stepery12 (12.9)Noed(svant stepery45 (27.1)Noed(svant stepery45 (27.1)Noed(svant stepery12 (12.9)Noed(svant stepery45 (27.1)Noed(svant stepery45 (27.1)Noed(svant stepery45 (27.1)Noed(svant stepery45 (25.1)Noed(svant stepery13 (12.1)Noed(svant stepery13 (12.1)Noed(svant stepery13 (12.1) <t< td=""><td>Genetic testing after diagnosis but before surgery</td><td>56 (32.4)</td></t<>	Genetic testing after diagnosis but before surgery	56 (32.4)
Laterally33 (5)Bilatera breast cancer13 (5)Unilatera breast cancer10 (73)010 (73)140 (55)253 (38,7)322 (16,1)332 (21)Uhowa32 (22)Uhowa98 (59,4)Negative98 (59,4)Positive98 (59,4)Positive98 (59,4)Positive67 (40,6)Uhowa8Positive87 (40,6)Uhowa8Positive87 (40,6)Uhowa86 (54,1)Positive87 (40,6)Uhowa86 (54,1)Positive87 (40,6)Uhowa86 (54,1)Vegative18 (92,2)Uhowa10 (7,8)Negative118 (92,2)Unowa10 (7,8)Negative118 (92,2)Unowa on on applicible60 (43,7)Unilater tat masteromy60 (43,7)Unilater tat masteromy42 (23,1)Nore10 (23)Nore10 (23)Nore10 (23)Nore10 (23)Nore10 (24)Vesadjivant chenotherapy45 (27,1)Nore10 (25)Nore20 (54,5)Nore20 (54,5)Nore20 (54,5)Nore20 (54,5)Nore20 (54,5)Nore20 (54,5)Nore20 (54,5)Nore20 (54,5)Nore20 (54,5)Nore20 (54,5)	Genetic testing after surgery	102 (59.0)
Bilderal breast cancer13 (5)Unitatral breast cancer10 (02)Unitatral breast cancer10 (7.3)1443 (35.3)143 (32.2)322 (16.1)3 (22.2)Unknown3 (22.2)Nodal status8 (59.4)Vestario9 (59.4)Unknown8 (59.4)Nogairve9 (59.4)Nogairve9 (59.4)Nogairve9 (59.4)Nogairve10 (7.8)Negairve9 (59.4)Nogairve10 (7.8)Negairve10 (7.8)None10 (7.6)No10 (7.6) <t< td=""><td>Laterality</td><td></td></t<>	Laterality	
Unilateral breast cancer160 (02.5)Clinical TSM stage0 (0.7)00 (0.7)140 (05.8)253 (08.7)333 (08.7)332 (02.1)332 (02.1)332 (02.1)432 (02.1)Vankown98 (09.4)Noaito98 (09.4)Positive98 (09.4)Positive98 (09.4)Positive98 (09.4)Positive98 (09.4)Positive98 (09.4)Positive98 (09.4)Positive98 (09.4)Positive98 (09.4)Positive98 (09.4)Positive86 (09.1)Negative10 (7.8)Positive80 (04.7)Unknown10 (7.8)Positive10 (7.8)Positive11 (27.9)None12 (12.1)Bilderal mastercomy12 (12.1)Bilderal mastercomy12 (12.1)Positive Instructive7Positive Instructive7Positive Instructive7Positive Instructive7Positive Instructive7Positive Instructiv	Bilateral breast cancer	13 (7.5)
Clinical TNM stage0010 (7.3)140 (5.8)253 (38.7)322 (16.1)332 (20.1)1432 (20.1)Unknown36Nodal stats96 (99.4)Vespaive67 (40.0)Unknown8Storgen coceptor stats8Forgen coceptor stats8Positive80 (54.1)Negaive73 (45.9)Unknown not applicable10 (7.8)Negaive10 (7.8)None12 (12.1)Bilateral mastectomy20 (3.6)None12 (12.1)None12 (12.1) </td <td>Unilateral breast cancer</td> <td>160 (92.5)</td>	Unilateral breast cancer	160 (92.5)
010 (7.3)149 (35.8)253 (38.7)322 (16.1)432 (2.2)Unknow36Nodal status98 (59.4)Positive67 (40.6)Unknown8Estrogen receptor status8Estrogen receptor status8 (54.1)Positive86 (54.1)Negativa73 (45.9)Unknown14HER2 status10 (78.)Positive10 (78.)Positive10 (78.)Unknown or not applicable10 (78.)Lumpectomy60 (34.7)Unilateral mastectomy21 (12.1)Biateral mastectomy21 (12.1)Biateral mastectomy21 (12.1)None*21 (12.1)None21 (12.1)None*21 (12.1)None21 (12.1)Keoadjuvant chemotherapy45 (27.1)Noedjuvant chemotherapy45 (27.1)None90 (54.6)No90 (54.6)No75 (45.5)Unknown75 (45.5)No10 (75, 155.5)No10 (75, 155.5)No<	Clinical TNM stage	
149 (35.8)253 (8.7)322 (16.1)43 (2.2)Unknown3 (2.2)Nodal status36Nodal status76 (40.6)Unknown8Setoreen receptor status76 (40.6)Negative86 (54.1)Negative86 (54.1)Negative73 (45.9)Unknown10 (7.8)Negative10 (7.8)Negative10 (7.8)Negative45Unknown or not applicable60 (34.7)Unknown or not applicable81 (50.9)Nore"42 (23.9)Nore"42 (23.9)Nore"<	0	10 (7.3)
2S3 (38.7)322 (16.1)432 (2.2)Unknown36Nodal status98 (59.4)Negative98 (59.4)Positive67 (40.6)Unknown8Estrogen receptor status8Positive73 (45.9)Unknown14HER2 status118 (92.2)Unknown or ot applicable60 (34.7)Negative10 (7.8)Negative90 (54.0)Noditarel mastectomy60 (34.7)Unlarel mastectomy88 (50.9)None"42.3)None"12 (12.1)Bilateral mastectomy88 (50.9)None"12 (12.1)None"12 (12.1)None"12 (12.1)None"12 (12.1)None"90 (54.0)Non"75 (45.5)Unknown75 (45.5)No10 (54.5)No75 (45.5)No90 (54.5)No10 (54.5) <trtr>No10 (5</trtr>	1	49 (35.8)
322 (16.1)43 (2.2)Unknown3 6Nodal starus98 (59.4)Positive67 (40.6)Unknown8Estrogen receptor status8Positive86 (54.1)Negaive73 (45.9)Unknown14HER2 starus10 (7.8)Negaive10 (7.8)Negaive10 (7.8)Negaive60 (34.7)Unknown or not applicable45Initial breast surgery60 (34.7)Unitarent mastectomy60 (34.7)Unitarent mastectomy21 (12.1)None"4 (2.3)None"4 (2.3)None"12 (72.9)Nonedurunt chemotherapy4 (2.1)None (12 (72.9)90 (54.6)Non7 (75 (55.5)Unknown7 (54.55.5)Non (75 (55.5)75 (45.5)Non (75 (45.5)75 (45.5)Non (75	2	53 (38.7)
43 (2)Unkown36Nodal staus96 (59.4)Negative67 (40.6)Unkown8Estregen receptor staus73 (45.9)Doktive14HER2 staus73 (45.9)Unknown on tot applicable10 (7.8)Negative10 (7.8)Negative118 (92.2)Unknown on tot applicable45Lindrectomy60 (34.7)Unilateral mastectomy21 (12.1)Bildref and statement21 (12.1)Bildref and statement21 (12.1)None*21 (12.1)None*121 (72.9)Nonedjuvant systemic therapy45 (27.1)Nonedjuvant systemic therapy45 (27.1)None (12.1)7Adjuvant chemotherapy7 (45.5)None (12.1)75 (45.5)<	3	22 (16.1)
Inknown36Nodi stutos98 (59.4)Negative98 (59.4)Positive67 (40.6)Unknown8Estrogen receptor status86 (54.1)Negative73 (45.9)Unknown14HER2 status10 (7.8)Negative10 (7.8)Negative118 (92.2)Unknown or not applicable60 (34.7)Unknown or not applicable21 (12.1)Bilateral mastectomy21 (12.1)Bilateral mastectomy21 (21.2)None*21 (22.9)None*21 (22.9)None*21 (22.9)None21 (22.9)None21 (22.9)None*21 (22.9)None*21 (22.9)None*21 (22.9)None21 (23.9)None21 (25.9)None21 (25.9) <td>4</td> <td>3 (2.2)</td>	4	3 (2.2)
Nodal status 98 (59.4) Postive 67 (40.6) Unknown 8 Estrogen receptor status 8 Postive 86 (54.1) Negative 10 (7.8) Negative 10 (7.8) Negative 10 (7.8) Negative 60 (34.7) Unknown or not applicable 60 (34.7) Unital treast surgery 21 (12.1) Bittard mastectomy 60 (34.7) Unitaleral mastectomy 21 (12.1) Bittard mastectomy 21 (12.1) Bittard mastectomy 21 (12.1) None ⁴ 45 (27.1) Nodajuvant systemic therapy 45 (27.1) Nodajuvant chemotherapy 7 Adjuvant chemotherapy 7 Adjuvant chemotherapy 7 Yes 90 (54.6) No 75 (45.5) Nohom 75 (45.5)	Unknown	36
Negative98 (59.4)Positive67 (40.6)Unknown67 (40.6)Unknown8Estrogen receptor status86 (54.1)Negative73 (45.9)Unknown73 (45.9)Unknown10 (7.8)Positive10 (7.8)Negative10 (7.8)Negative118 (92.2)Unknown or not applicable60 (34.7)Unitateral mastectomy60 (34.7)Unitateral mastectomy60 (34.7)Unitateral mastectomy8 (50.9)None*4 (2.3)Neoadjuvant systemic therapy90 (54.0)None Unitateral mastectomy7Adjuvant chemotherapy70 (54.5)None Teapper7Adjuvant chemotherapy90 (54.5)None Teapper8Yes90 (54.5)None Teapper8Adjuvant chation therapy8Yes75 (45.5)None None None None None None None None	Nodal status	
Positive 67 (40.0) Unknown 8 Estrogen receptor status 8 Positive 86 (54.1) Negative 73 (45.9) Unknown 73 (45.9) Unknown 14 HER2 status 10 (7.8) Positive 10 (7.8) Negative 118 (92.2) Unknown or not applicable 45 Initial breast surgery 11 Lumpectomy 60 (34.7) Unitaral mastectomy 8 (50.9) None* 4 (2.3) None* 4 (2.3) None* 121 (72.9) None adjuvant chemotherapy 0 (0.0) Unknown 7 Adjuvant chemotherapy 90 (54.6) No 7 (54.5) Nown 8 Adjuvant chemotherapy 90 (54.6) No 8 Adjuvant chemotherapy 90 (54.6) No 8 Nown 8 Adjuvant chemotherapy 90 (54.6) <t< td=""><td>Negative</td><td>98 (59.4)</td></t<>	Negative	98 (59.4)
Uknown 8 Estrogen receptor status 86 (54.1) Positive 86 (54.9) Negative 73 (45.9) Unknown 14 HER2 status 10 (7.8) Positive 10 (7.8) Negative 10 (7.8) Negative 118 (92.2) Unknown on not applicable 46 Initial breast surgery 21 (12.1) Bilateral mastectomy 60 (34.7) Unilateral mastectomy 60 (34.7) Unilateral mastectomy 60 (34.7) Unilateral mastectomy 60 (34.7) Unilateral mastectomy 88 (50.9) None ⁴ 4 (2.3) Neoadjuvant systemic therapy 88 (50.9) None ⁴ 4 (2.3) Neoadjuvant systemic therapy 90 (50.4) Noone (12) (Vargen) 7 Adjuvant chemotherapy 90 (54.6) No 75 (45.5) Unknown 8 Adjuvant radiation therapy 75 (45.5) No 75 (45.5) No <	Positive	67 (40.6)
Estrogen receptor status 86 (54.) Positive 73 (45.9) Negative 73 (45.9) Unknown 14 HER2 status 10 (7.8) Positive 18 (92.2) Unknown or not applicable 60 (34.7) Lumpectomy 60 (34.7) Unital mastectomy 21 (12.1) Bilateral mastectomy 21 (21.2) None ^a 4 (2.3) None ^a 5 (27.1) None (15.0) 7 Adjuvant systemic therapy 0 (0.0) Unknown 7 Adjuvant chemotherapy 7 None (15.0) 7 None (15.0) 75 (45.5) Unknown 8 Yes 75 (45.5) None (15.0) 75 (45.5)	Unknown	8
Positive 86 (54.1) Negative 73 (45.9) Unknown 14 HER2 status 10 (7.8) Positive 10 (7.8) Negative 118 (92.2) Unknown or not aptificable 45 Initial breast surgery 60 (34.7) Lumpectomy 60 (34.7) Unitateral mastectomy 21 (12.1) Bilateral mastectomy 88 (50.9) None ⁴ 88 (50.9) None ⁴ 45 (27.1) None (121 (72.9) 88 (50.9) None (121 (72.9) 84 (50.9) None (121 (72.9) 90 (54.6) Non (121 (72.9) 90 (54.6) Non	Estrogen receptor status	
Negative 73 (45.9) Unknown 14 HER2 status 10 (7.8) Positive 10 (7.8) Negative 118 (92.2) Unknown or not applicable 45 Initial breast surgery 60 (34.7) Unilateral mastectomy 60 (34.7) Unilateral mastectomy 60 (34.7) Unilateral mastectomy 88 (50.9) None ⁴ 4 (2.3) None ⁶ 4 (2.3) None ⁶ 4 (2.3) None ⁶ 4 (2.3) None ⁶ 4 (2.7) None (herapy) 0 (0.0) Unknown 4 (2.7) Noadjuvant chemotherapy 0 (0.0) Unknown 4 (2.7) Noadjuvant chemotherapy 0 (0.0) Unknown 7 (5 (5.5) None 9 (5 (4.5) Adjuvant therapy 9 (5 (4.5) No 9 (5 (5.5) No 8 Adjuvant radiation therapy 7 (5 (5.5) No 9 (5 (5.5) No	Positive	86 (54.1)
Uknown 14 HER2 status 10 (7.8) Positive 118 (92.2) Uknown or not applicable 18 Initial breast surgery 60 (34.7) Lumpectomy 60 (34.7) Uhitaral mastectomy 21 (12.1) Bilateral mastectomy 88 (50.9) None ⁴ 4 (2.3) Neoadjuvant systemic therapy 4 (2.3) None 121 (72.9) Noadjuvant chemotherapy 45 (27.1) Noodjuvant chemotherapy 40 (0.0) Unknown 7 Adjuvant chemotherapy 90 (54.6) No 75 (45.5) Unknown 8 Adjuvant radiation therapy 8 Yes 75 (45.5) No 8 Adjuvant radiation therapy 90 (54.6) No 75 (45.5) Unknown 8 Adjuvant radiation therapy 90 (54.6) No 90 (54.6) No 90 (54.6) No 90 (54.6) No	Negative	73 (45.9)
HER2 status 10 (7.8) Positive 118 (92.2) Ivextime 45 Initial breast surgery 60 (34.7) Lumpectomy 60 (34.7) Unitateral mastectomy 21 (12.1) Bilateral mastectomy 21 (12.1) Bilateral mastectomy 42 (3.3) None ⁴ 42.3) Noney 42 (3.7) Noney 121 (72.9) Noney 121 (72.9) Noney 45 (27.1) Noney 7 Adjuvant chemotherapy 45 (27.1) No 7 Adjuvant ndecrine therapy 90 (54.6) No 7 Adjuvant rediation therapy 8 Viknown 8 Adjuvant rediation therapy 90 (54.6) No 90 (54.6) No 90 (54.6) No	Unknown	14
Positive 10 (7.8) Negative 118 (92.2) Unknown or not applicable 45 Initial breast surgery 60 (34.7) Lumpectomy 60 (34.7) Unilateral mastectomy 60 (34.7) Unilateral mastectomy 60 (34.7) Bilaeral mastectomy 60 (34.7) Weideral mastectomy 60 (34.7) None ⁴ 61 (21.7) None ⁴ 62 (21.1) None 121 (72.9) Neoadjuvant chemotherapy 45 (27.1) Neoadjuvant chemotherapy 70 (00.0) Unknown 7 Adjuvant chemotherapy 90 (54.6) No 75 (45.5) Unknown 8 Adjuvant radiation therapy 75 (45.5) No 75 (45.5) <	HER2 status	
Negative 118 (9.2.2) Unknown or not applicable 45 Initial breast surgery 60 (34.7) Lumpectomy 60 (34.7) Unilateral mastectomy 21 (12.1) Bilateral mastectomy 88 (50.9) None ⁴ 4 (2.3) Neoadjuvant systemic therapy 4 (2.3) Neoadjuvant systemic therapy 45 (27.1) Neoadjuvant chemotherapy 45 (27.1) Neoadjuvant chemotherapy 45 (27.1) Neoadjuvant chemotherapy 0 (0.0) Unknown 7 Adjuvant chemotherapy 90 (54.6) No 75 (45.5) Unknown 8 Adjuvant radiation therapy 75 (45.5) No 75 (45.5) No 75 (45.5) Unknown 8	Positive	10 (7.8)
Uknown or not applicable 45 Initial breast surgery 60 (34.7) Lumpectomy 60 (34.7) Unilateral mastectomy 21 (12.1) Bilateral mastectomy 88 (50.9) None ^a 4 (2.3) Neoadjuvant systemic therapy 4 (2.3) Neoadjuvant systemic therapy 45 (27.1) Neoadjuvant chemotherapy 45 (27.1) Neoadjuvant endocrine therapy 0 (0.0) Unknown 7 Adjuvant chemotherapy 90 (54.6) No 75 (45.5) Unknown 8 Adjuvant radiation therapy 8 Ves 90 (54.6) No 75 (45.5) Unknown 8 Adjuvant radiation therapy 55 (45.5) No 75 (45.5) No 75 (45.5) No 75 (45.5) No 90 (54.6) No 90 (54.6) No 90 (54.6) No 8 No 90 (54.6) No <t< td=""><td>Negative</td><td>118 (92.2)</td></t<>	Negative	118 (92.2)
Itilal breast surgery 60 (34.7) Lumpectomy 60 (34.7) Unilateral mastectomy 21 (12.1) Bilateral mastectomy 88 (50.9) None ^a 4 (2.3) None ^a 4 (2.3) Neoadjuvant systemic therapy 45 (27.1) Neoadjuvant chemotherapy 45 (27.1) Neoadjuvant endocrine therapy 0 (0.0) Unknown 7 Adjuvant chemotherapy 90 (54.6) No 15 (45.5) Unknown 75 (45.5) No 90 (54.6) No 75 (45.5) No 90 (54.6) No 75 (45.5) No 90 (54.6) No 8	Unknown or not applicable	45
Lumpectomy 60 (34.7) Unilateral mastectomy 21 (12.1) Bilateral mastectomy 88 (50.9) None ^a 4 (2.3) Neoadjuvant systemic therapy 121 (72.9) Neoadjuvant chemotherapy 45 (27.1) Neoadjuvant endocrine therapy 0 (0.0) Unknown 7 Adjuvant chemotherapy 90 (54.6) No 125 (45.5) Unknown 8 Adjuvant radiation therapy 8 Ves 75 (45.5) No 90 (54.6) No 8 Unknown 8	Initial breast surgery	
Initiateral mastectomy 21 (12.1) Bilateral mastectomy 88 (50.9) None ^a 4 (2.3) Neoadjuvant systemic therapy 4 (2.3) None 121 (72.9) Neoadjuvant chemotherapy 45 (27.1) Neoadjuvant endocrine therapy 0 (0.0) Unknown 7 Adjuvant chemotherapy 90 (54.6) No 75 (45.5) Unknown 8 Adjuvant radiation therapy 75 (45.5) No 90 (54.6) No 90 (54.6) No 90 (54.6) No 8 Adjuvant radiation therapy 90 (54.6) No 90 (54.6) No 90 (54.6)	Lumpectomy	60 (34.7)
Bilateral mastectomy88 (50.9)None ^a 4 (2.3)Neoadjuvant systemic therapy121 (72.9)Neoadjuvant chemotherapy45 (27.1)Neoadjuvant endocrine therapy0 (0.0)Unknown7Adjuvant chemotherapy90 (54.6)No75 (45.5)Unknown8Adjuvant radiation therapy8Yes90 (54.6)No8Adjuvant radiation therapy90 (54.6)Ves75 (45.5)Unknown8Adjuvant radiation therapy90 (54.6)No90 (54.6)No8	Unilateral mastectomy	21 (12.1)
None ^a 4 (2.3) Neoadjuvant systemic therapy 121 (72.9) Neoadjuvant chemotherapy 45 (27.1) Neoadjuvant endocrine therapy 0 (0.0) Unknown 7 Adjuvant chemotherapy 90 (54.6) No 75 (45.5) Unknown 8 Adjuvant radiation therapy 90 (54.6) No 75 (45.5) Unknown 8	Bilateral mastectomy	88 (50.9)
Neoadjuvant systemic therapy 121 (72.9) None 121 (72.9) Neoadjuvant chemotherapy 45 (27.1) Neoadjuvant endocrine therapy 0 (0.0) Unknown 7 Adjuvant chemotherapy 90 (54.6) No 75 (45.5) Unknown 8 Adjuvant radiation therapy 90 (54.6) Ves 75 (45.5) No 90 (54.6) No 8	None ^a	4 (2.3)
None 121 (72.9) Neoadjuvant chemotherapy 45 (27.1) Neoadjuvant endocrine therapy 0 (0.0) Unknown 7 Adjuvant chemotherapy 90 (54.6) No 75 (45.5) Unknown 8 Adjuvant radiation therapy 90 (54.6) No 75 (45.5) Unknown 8 Adjuvant radiation therapy 90 (54.6) Ves 75 (45.5) No 8 Adjuvant radiation therapy 8 Yes 75 (45.5) No 90 (54.6) Ves 75 (45.5) No 90 (54.6)	Neoadiuvant systemic therapy	
Neoadjuvant chemotherapy 45 (27.1) Neoadjuvant endocrine therapy 0 (0.0) Unknown 7 Adjuvant chemotherapy 7 Adjuvant chemotherapy 90 (54.6) No 75 (45.5) Unknown 8 Adjuvant radiation therapy 75 (45.5) No 90 (54.6) Ves 75 (45.5) No 90 (54.6) Unknown 8	None	121 (72.9)
Neoadjuvant endocrine therapy0 (0.0)Unknown7Adjuvant chemotherapy7Yes90 (54.6)No75 (45.5)Unknown8Adjuvant radiation therapy8Yes75 (45.5)No90 (54.6)Unknown8Adjuvant radiation therapy8Yes75 (45.5)No90 (54.6)Unknown8	Neoadiuvant chemotherapy	45 (27.1)
Unknown 7 Adjuvant chemotherapy 7 Yes 90 (54.6) No 75 (45.5) Unknown 8 Adjuvant radiation therapy Yes Yes 75 (45.5) No 8 Adjuvant radiation therapy Yes Yes 75 (45.5) No 90 (54.6) Unknown 8	Neoadjuvant endocrine therapy	0 (0.0)
Adjuvant chemotherapy 90 (54.6) Yes 90 (54.6) No 75 (45.5) Unknown 8 Adjuvant radiation therapy 75 (45.5) Yes 75 (45.5) No 90 (54.6) Unknown 90 (54.6) Unknown 8	Unknown	7
Yes 90 (54.6) No 75 (45.5) Unknown 8 Adjuvant radiation therapy 75 (45.5) No 90 (54.6) Unknown 8	Adjuvant chemotherapy	
No 75 (45.5) Unknown 8 Adjuvant radiation therapy 75 (45.5) Yes 75 (45.5) No 90 (54.6) Unknown 8	Yes	90 (54.6)
Unknown 8 Adjuvant radiation therapy Yes 75 (45.5) No 90 (54.6) Unknown 8	No	75 (45.5)
Adjuvant radiation therapy Yes 75 (45.5) No 90 (54.6) Unknown 8	Unknown	8
Yes 75 (45.5) No 90 (54.6) Unknown 8	Adjuvant radiation therapy	-
No 90 (54.6) Unknown 8	Yes	75 (45 5)
Unknown 8	No	90 (54.6)
	Unknown	8

 TNM tumor-node metastasis, HER human epidermal growth factor receptor

^a This included three stage 4 patients who at presentation underwent no primary breast surgery and one patient with no breast primary tumor who underwent axillary lymph node dissection only as initial surgery

11 contralateral breast cancers. The estimated 5-year freedom from breast cancer was 84 % (95 % CI 77–92 %) (Table 2). There was no significant difference across surgery types for this combined end point (p = 0.51) or for local-regional recurrence (p = 0.57). However, women undergoing BM saw a significantly reduced risk of contralateral breast cancer in unadjusted analysis (hazard ratio [HR], 0.12; 95 % CI 0.02–0.78; p = 0.03) (Fig. 3) and adjusted analysis (HR 0.14; 95 % CI 0.02–0.83; p = 0.03). One woman did experience contralateral breast cancer after skin-sparing contralateral prophylactic mastectomy. The contralateral breast cancer was in the mastectomy flap at the periphery of the breast.

Patients Presenting with Bilateral Cancer

Among 13 patients with bilateral breast cancer, 9 (69 %) underwent BM, and 4 (31 %) underwent bilateral lumpectomy. None of the four women electing bilateral lumpectomy knew of their BRCA mutation status at the time of surgical decision making, and three of the four women subsequently underwent BM (2 for risk reduction, 1 for margin control). Of the nine women electing BM, five knew of their mutation status before surgery, and four were unaware of their mutation. The estimated 5-year freedom from breast cancer in the bilateral cancer subset was 92 % (77–100 %).

DISCUSSION

Identification of BRCA mutation status influences the surgical decision making of patients with a diagnosis of breast cancer.^{14,15} Our study demonstrated that knowledge of BRCA mutation carrier status before surgical treatment has a significant impact on the type of surgical procedure patients choose. The findings showed that 83 % of the patients with known BRCA mutation status underwent BM compared with 29 % of the patients who were unaware of their BRCA mutation status at the time of their index surgery for breast cancer.

Comparison of outcomes between breast conservation and mastectomy for women with deleterious BRCA mutation is an area of ongoing debate and research. It is unlikely that a randomized clinical trial will ever be conducted. Therefore, results from retrospective studies must be used to answer this question.

Multiple studies have evaluated the rate of ipsilateral breast cancer recurrence in BRCA mutation carriers versus noncarriers, with conflicting results. In some studies, breast cancer patients with BRCA1/BRCA2 mutation who underwent lumpectomy for breast cancer had a greater risk of ipsilateral breast cancer than patients with sporadic breast cancer, and the risk increased with longer follow-up periods.^{16–18} The 10-year cumulative incidence of ipsilateral-breast cancer was 27 % for BRCA mutation carriers compared with 4 % for sporadic control subjects (HR 3.9; 95 % CI 1.1–13.8; p = 0.03).¹⁰ In comparison, other studies have shown no significant difference in local recurrence rates between BRCA mutation carriers and noncarriers among patients treated with lumpectomy and radiation.^{19–21}

In terms of contralateral breast cancer risk, a metaanalysis showed that BRCA1/BRCA2 mutation carriers have a 3.5-fold increase in relative risk of contralateral breast cancer after a first breast cancer compared with noncarriers.^{10–12,22} A meta-analysis of 18 retrospective and 2 prospective cohorts reported on cumulative risk of secondary primary contralateral breast cancer in 1324 carriers of BRCA1/BRCA2 mutation. The cumulative 10-year risk of contralateral breast cancer was 27 % (95 % CI 21– 33 %) for BRCA1 mutation carriers and 19 % (95 % CI 15–23 %) for BRCA2 mutation carriers compared with 5 % (95 % CI 3–7 %) for non-BRCA carriers.²³

In our study, the women undergoing BM showed a significantly lower risk for contralateral breast cancer than those maintaining their contralateral breast.

Given recent evidence demonstrating higher rates of contralateral breast cancer development in this population, BM at the time of cancer diagnosis has been suggested as a reasonable surgical choice for BRCA mutation carriers.^{21,24,25} Furthermore, Metcalfe et al.²⁶ reported a study with a 20-year follow-up period in which BRCA mutation carriers with breast cancer who underwent bilateral mastectomy had a 48 % reduction in death from breast cancer compared with women who underwent unilateral mastectomy (HR 0.52; 95 % CI 0.29–0.93; p = 0.03). Similarly, Heemskerk-Gerritsen et al.²⁷ reported a lower mortality rate for BRCA mutation patients with unilateral breast



FIG. 3 Kaplan–Meier estimates for the development of contralateral breast cancer among 156 female BRCA1/BRCA2 mutation carriers presenting with unilateral stages 0–3 breast cancer

	5-year % (95 % CI)	10-year % (95 % CI)	Unadjusted p value	p value adjusted for age and stage
Local-regional recurrence				
Overall	96.2 (92.5-100)	83.7 (72.0–97.2)		
Lumpectomy	95.0 (88.3-100)	80.0 (64.5-98.7)	0.57	0.38
Mastectomy	97.0 (92.9–100)	92.4 (83.2–100)		
New contralateral primary	breast cancer			
Overall	97.2 (94.1-100)	72.6 (58.3-90.5)		
Lumpectomy or UM	92.6 (84.9-100)	64.3 (47.9–86.4)	0.03	0.03
BM	100	83.3 (58.3-100)		
Any subsequent breast car	ncer event			
Overall	84.1 (77.0–91.8)	56.4 (42.5–74.9)		
Lumpectomy	89.4 (80.0-100)	NA ^a	0.51	0.36
UM	83.6 (64.9-100)	NA ^a		
BM	79.7 (68.6–92.5)	NA ^a		

 TABLE 2
 Outcomes among 156 female subjects presenting with unilateral breast cancer

UM unilateral mastectomy, BM bilateral mastectomy, NA not available

^a Sample size and number remaining at risk were too small to estimate

cancer undergoing contralateral prophylactic mastectomy than for the surveillance group (9.6 and 21.6 per 1000 person-years of observation, respectively; adjusted HR 0.19; 95 % CI 0.29–0.82).

In our study of patients identified as BRCA mutation carriers after definitive surgery for their index breast cancer who underwent UM or lumpectomy, 59 % (39/66) ultimately underwent BM. Knowledge of BRCA mutation carrier status at the time of surgical decision making for their index cancer could have eliminated subsequent breast operations, which pose additional cost and morbidity, because many of these patients may have chosen to undergo BM as their initial operation. Genetic testing results can be difficult to obtain in a timely manner. In our practice, we currently prioritize the referral of patients meeting the criteria for genetic testing who will undergo primary surgery so that the information can be available before surgery.

The National Comprehensive Cancer Network guidelines recommend breast screening with magnetic resonance imaging (MRI) annually for BRCA mutation carriers 25–29 years of age, and for BRCA mutation carriers 30–75 years of age annual mammograms, and annual breast MRI.²⁸ The combination of MRI and mammogram screening is based on the superior sensitivity shown through this approach.^{29,30} Patients with BRCA deleterious mutations at our institution are followed every 6 months with a breast exam, an annual MRI, and an annual mammography. Our study demonstrated that patients with known BRCA+ mutation status presented with a significantly earlier stage of breast cancer than patients unaware of their BRCA mutation carrier status. This is most likely

due to high-risk screening and patient awareness in BRCA mutation carriers.

Although this study demonstrated clinically relevant information for BRCA mutation carriers, several imitations should be noted. This was a retrospective study from a single institution, and it had information gaps including patients' preferences and physician recommendations, which also influence surgical decision making. Because not all the patients underwent their index surgical treatment at our institution, some clinical features such as clinical stage were missing for approximately 20 % of the patients. Yet, by including all the patients whose index breast surgery choice and timing of mutation testing could be discerned from sources including patient surveys, we were able to present a larger and more inclusive sample size for the primary aim. Finally, the moderate sample size and the relatively short median follow-up period of 41 months meant that analyses of outcomes such as recurrence were limited in precision, with wide confidence intervals for some estimates, and by low power for comparison across surgery groups.

In summary, this study provides strong evidence that knowledge of BRCA+ mutation status has an impact on definitive surgical decision making in index breast cancer treatment. The rates of bilateral mastectomy were significantly higher among the patients with known BRCA mutation status than among those whose BRCA mutation status was not known at time of surgical treatment. Identification of BRCA mutation after surgical treatment of the index breast cancer led to additional future surgeries for patients who underwent lumpectomy or UM as the surgical management of their initial unilateral breast cancer.

A. Chiba et al.

Bilateral mastectomy decreased contralateral breast cancer risk significantly. This study further supports the importance of genetic testing before definitive surgical treatment of the index breast cancer of patients with elevated risk for genetic mutation.

ACKNOWLEDGMENT This research was supported in part by a generous gift from the David F. and Margaret T. Grohne Family Foundation, an NCI Specialized Program of Research Excellence (SPORE) in Breast Cancer (CA116201), NIH Grants (CA116167 and CA192393), and a grant from the Breast Cancer Research Foundation

REFERENCES

- Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. *Science*. 1994;266:66–71. doi:10.1126/science.7545954.
- Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. *Nature*. 1995;378:789– 92. doi:10.1038/378789a0.
- Risch HA, McLaughlin JR, Cole DEC, et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kincohort study in Ontario, Canada. J Natl Cancer Inst. 2006;98:1694–706. doi:10.1093/jnci/djj465.
- Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. *Am J Hum Genet*. 1998;62:676–89. doi:10.1086/301749.
- Vasen HFA, Tesfay E, Boonstra H, et al. Early detection of breast and ovarian cancer in families with BRCA mutations. *Eur J Cancer*. 2005;41:549–54. doi:10.1016/j.ejca.2004.10.029.
- Evans DG, Shenton A, Woodward E, Lalloo F, Howell A, Maher ER. Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: risks of breast/ ovarian cancer quoted should reflect the cancer burden in the family. *BMC Cancer*. 2008;8:155. doi:10.1186/1471-2407-8-155.
- Lokich E, Stuckey A, Raker C, Wilbur JS, Laprise J, Gass J. Preoperative genetic testing affects surgical decision making in breast cancer patients. *Gynecol Oncol.* 2014;134:326–30. doi:10. 1016/j.ygyno.2014.05.028.
- Mai PL, Lagos VI, Palomares MR, Weitzel JN. Contralateral risk-reducing mastectomy in young breast cancer patients with and without genetic cancer risk assessment. *Ann Surg Oncol.* 2008;15:3415–21. doi:10.1245/s10434-008-0160-3.
- Tercyak KP, Peshkin BN, Brogan BM, et al. Quality of life after contralateral prophylactic mastectomy in newly diagnosed highrisk breast cancer patients who underwent BRCA1/2 gene testing. *J Clin Oncol.* 2007;25:285–91. doi:10.1200/JCO.2006.07.3890.
- Garcia-Etienne CA, Barile M, Gentilini OD, et al. Breast-conserving surgery in BRCA1/2 mutation carriers: are we approaching an answer? *Ann Surg Oncol.* 2009;16:3380–7. doi:10.1245/s10434-009-0638-7.
- Valachis A, Nearchou AD, Lind P. Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis. *Breast Cancer Res Treat*. 2014;144:443–55. doi:10.1007/s10549-014-2890-1.
- Graeser MK, Engel C, Rhiem K, et al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2009;27:5887–92. doi:10.1200/JCO.2008.19.9430.
- Therneau T, Grambsch P. Modeling survival data: extending the Cox model. *Technometrics*. 2002;44:85–6. doi:10.1198/tech.2002.s656.
- Weitzel JN, McCaffrey SM, Nedelcu R, MacDonald DJ, Blazer KR, Cullinane CA. Effect of genetic cancer risk assessment on

surgical decisions at breast cancer diagnosis. Arch Surg. 2003;138:1323–8. doi:10.1001/archsurg.138.12.1323.

- Schwartz MD, Lerman C, Brogan B, et al. Impact of BRCA1/ BRCA2 counseling and testing on newly diagnosed breast cancer patients. *J Clin Oncol.* 2004;22:1823–9. doi:10.1200/JCO.2004. 04.086.
- Pierce LJ, Phillips KA, Griffith KA, et al. Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. *Breast Cancer Res Treat.* 2010;121:389–98. doi:10.1007/s10549-010-0894-z.
- Mavaddat N, Peock S, Frost D, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst. 2013;105:812–22. doi:10.1093/ jnci/djt095.
- Trainer AH, Lewis CR, Tucker K, Meiser B, Friedlander M, Ward RL. The role of BRCA mutation testing in determining breast cancer therapy. *Nat Rev Clin Oncol.* 2010;7:708–17. doi:.10.1038/nrclinonc.2010.175.
- Pierce LJ, Levin AM, Rebbeck TR, et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol. 2006;24:2437–43. doi:10.1200/JCO.2005.02.7888.
- 20. Kirova YM, Savignoni A, Sigal-Zafrani B, et al. Is the breastconserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature. *Breast Cancer Res Treat.* 2010;120:119–26.
- Robson M, Levin D, Federici M, et al. Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. J Natl Cancer Inst. 1999;91:2112–7.
- Metcalfe K, Lynch HT, Ghadirian P, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. *J Clin Oncol.* 2004;22:2328–35. doi:10.1200/JCO.2004.04.033.
- Molina-Montes E, Pérez-Nevot B, Pollán M, Sánchez-Cantalejo E, Espín J, Sánchez MJ. Cumulative risk of second primary contralateral breast cancer in BRCA1/BRCA2 mutation carriers with a first breast cancer: a systematic review and meta-analysis. *Breast*. 2014;23:721–42. doi:10.1016/j.breast.2014.10.005.
- Haffty BG, Harrold E, Khan AJ, et al. Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. *Lancet*. 2002;359:1471–7. doi:10.1016/S0140-6736(02)08434-9.
- Pierce LJ, Strawderman M, Narod SA, et al. Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. *J Clin Oncol.* 2000;18:3360–9.
- Metcalfe K, Gershman S, Ghadirian P, et al. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. *BMJ*. 2014;348:g226. doi:10.1136/bmj.g226.
- Heemskerk-Gerritsen BA, Brekelmans CT, Menke-Pluymers MB et al. Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic. *Ann Surg Oncol.* 2007;14:3335–44. doi:10.1245/s10434-007-9449-x.
- National Comprehensive Cancer Center Guidelines. Genetic/familial high risk assessment: breast and ovarian (verson 2.2016). http://www.nccn.org/professionals/physician_gls/PDF/genetics_ screening.pdf. Accessed 20 March 2016.
- Warner E, Messersmith H, Causer P, Eisen A, Shumak R, Plewes D. Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer. *Ann Intern Med.* 2008;148:671– 9. doi:10.7326/0003-4819-148-9-200805060-00007.
- 30. Lord SJ, Lei W, Craft P, et al. A systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer. *Eur J Cancer*. 2007;43:1905–17. doi:10.1016/j.ejca.2007.06.007.